
Ozempic and Mounjaro can have a surprising effect on your brain
Popular medications used to treat obesity and type 2 diabetes, including semaglutide and tirzepatide, may have effects beyond weight loss and blood sugar control. These drugs also influence biological processes involved in brain function, raising the question of whether they could help preserve memory and thinking skills.
To examine this possibility, researchers from the University of Gothenburg and the University of Copenhagen examined existing scientific evidence at the invitation of the journal. Science.
Studies involving animals suggest that GLP-1 drugs may influence learning and memory. However, research involving humans has produced less consistent results. Analyzes of patients’ medical records revealed an association between GLP-1 treatment and a reduced risk of dementia in people with type 2 diabetes. These observational results are encouraging, but they cannot determine whether the drugs themselves are responsible for the lower risk.
More definitive results have also raised questions. In Novo Nordisk’s EVOKE and EVOKE+ clinical trials, semaglutide failed to slow the progression of early Alzheimer’s disease. Although the treatment affected several biological markers associated with Alzheimer’s disease, these changes did not translate into a measurable slowing of the disease.
Why weight loss drugs can still benefit the brain
Despite disappointing results in Alzheimer’s disease, researchers believe GLP-1 drugs may still provide cognitive benefits to certain patient groups.
People with obesity or type 2 diabetes sometimes have difficulty paying attention, planning, and processing information quickly. These cognitive problems are often associated with metabolic health and blood vessel function, suggesting that they may respond differently to treatment compared to changes caused by Alzheimer’s disease.
Improving blood sugar regulation, metabolism, or vascular health could potentially help preserve cognitive abilities, even if the same medications cannot slow an established neurodegenerative disease.
Stina Börchers, first author of the review and a researcher affiliated with the University of Gothenburg and the University of Copenhagen, emphasizes the need to determine whether starting treatment earlier could make a difference.
“We need to determine whether these treatments can help obese or diabetic people preserve their cognitive abilities, especially if treatment is started before cognitive problems set in. It is also important to identify patients who could benefit from them,” explains Stina Börchers.
Unlock new treatments to protect memory
A central unanswered question is how GLP-1 drugs might influence the brain. Their potential cognitive effects could result from improvements in metabolic health, direct actions in the brain, or a combination of both.
Understanding these mechanisms could help researchers identify patients most likely to benefit and potentially lead to drugs designed specifically to support memory and other thinking skills.
Christoffer Clemmensen, lead author of the review and head of a research group at the University of Copenhagen, sees an opportunity to use increasingly advanced treatments for obesity to explore the link between metabolism and the brain.
“Obesity drugs are becoming more and more sophisticated, providing new opportunities to understand how metabolic regulation influences brain function. By unraveling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function,” explains Christoffer Clemmensen.
Researchers are calling for clinical trials assessing memory, attention and other cognitive abilities early in treatment. Tracking these changes over time could help determine whether GLP-1 drugs actually protect brain function and who might benefit most.
They also point out that the treatment is not without potential downsides, particularly for the elderly and the physically frail. Rapid weight loss can lead to reduced muscle mass, which can weaken physical function and negate some of the possible benefits.
Close monitoring will therefore be essential as researchers study whether current weight loss and diabetes drugs could eventually provide new ways to protect the brain.
Gn Health